2023
DOI: 10.1186/s13045-023-01497-3
|View full text |Cite
|
Sign up to set email alerts
|

Recent advances in targeted strategies for triple-negative breast cancer

Shuangli Zhu,
Yuze Wu,
Bin Song
et al.

Abstract: Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited. The search for more effective therapies is urgent. Multiple targeted therapeutic strategies have emerged according to the specific molecules and signaling pathways expressed … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
45
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 66 publications
(45 citation statements)
references
References 292 publications
0
45
0
Order By: Relevance
“…Targeted drugs that intended for BRCA1/2 mutations, intracellular signaling pathways, immune checkpoint have brought great opportunities to improve the prognosis of TNBC patients. 374 …”
Section: Clinical Advancements In Dcis and Idcmentioning
confidence: 99%
See 2 more Smart Citations
“…Targeted drugs that intended for BRCA1/2 mutations, intracellular signaling pathways, immune checkpoint have brought great opportunities to improve the prognosis of TNBC patients. 374 …”
Section: Clinical Advancements In Dcis and Idcmentioning
confidence: 99%
“…Ongoing research is exploring additional targeted therapies to inhibit intracellular signaling pathways such as PI3K/AKT/mTOR, EGFR, Notch signaling, and STAT3 signaling, aiming to evaluate their safety and effectiveness in TNBC patients. 374 However, the current therapeutic options for TNBC are limited compared to ER-positive and HER2-positive breast cancer due to the absence of well-defined targets and the inherent heterogeneity of TNBC itself. As a result, effectively treating TNBC remains a significant challenge that needs to be addressed.…”
Section: Clinical Advancements In Dcis and Idcmentioning
confidence: 99%
See 1 more Smart Citation
“…Despite the advances in breast cancer treatment, the prognosis for TNBC patients has seen little improvement over the past few decades 3 . Novel therapeutic strategies, including poly (ADP-ribose) polymerase (PARP) inhibition, immunotherapy, and inhibition of signaling pathways such as the androgen receptor, PI3K/AKT/mTOR, Notch, and EGFR pathways, are being actively explored 4 . Indeed, PARP inhibitors such as olaparib and veliparib 5 , immune checkpoint inhibitors such as pembrolizumab 6 , 7 , and antibody-drug conjugates (ADCs) such as sacituzumab govitecan 8 have demonstrated activity in a subset of TNBC patients.…”
Section: Introductionmentioning
confidence: 99%
“…In recent years, the appreciation of TNBC has led to the development of targeted therapy and immunotherapy, including the application of PI3K/AKT/mTOR inhibitors, EGFR inhibitors, Notch inhibitors, PARP inhibitors, antibody-drug conjugates, and immune-checkpoint inhibitors. The revolutionizing therapeutic landscape provides the opportunities for advanced-stage disease and early stage TNBC patients. , Surgical adjuvant chemotherapy has been the main therapy for TNBC . However, due to the lack of chemotherapy-specific targeting, surgical adjuvant chemotherapy has difficulty removing all lesions, and the small number of remaining metastases will eventually lead to tumor relapse .…”
mentioning
confidence: 99%